CollPlant Biotechnologies (CLGN) Research & Development (2017 - 2026)

CollPlant Biotechnologies' Research & Development history runs 10 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• Quarterly Research & Development fell 20.29% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (down 24.03% YoY) and the FY2025 annual result came in at $8.2 million, down 22.14% from the prior year.
• Research & Development was $1.7 million for Q1 2026 at CollPlant Biotechnologies, down from $2.0 million in the prior quarter.
• Across five years, Research & Development topped out at $3.1 million in Q4 2023 and bottomed at $1.7 million in Q1 2026.
• A 5-year average of $2.4 million and a median of $2.5 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development surged 45.55% — and 2025, when it fell 27.19%.
• CollPlant Biotechnologies' Research & Development stood at $2.6 million in 2022, then advanced by 18.05% to $3.1 million in 2023, then slipped by 18.31% to $2.5 million in 2024, then decreased by 22.14% to $2.0 million in 2025, then fell by 15.25% to $1.7 million in 2026.
• Business Quant data shows CLGN's Research & Development at $1.7 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.